Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don’t clinical trials look like America?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for an interview with Michael Chan, the man tasked with convincing biotech companies to go public on the Hong Kong Stock Exchange, about how that experiment is going. Then we dig into saga surrounding Clovis Oncology, which went from a Wall Street darling to a cautionary tale before paying an arguably minuscule price for its alleged misdeeds. And then ProPublica reporter Caroline Chen joins us to discuss why African-Americans are vastly underrepresented in cancer clinical trials. Finally, there’s a lightning round, exploring an odd move by PhRMA, a second act for an accused insider trader, and the drug industry’s latest star turn in Hollywood.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy